Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Dose Escalation Study of TAS-116 in Advanced Solid Tumors
jRCT2080222394Phase 1Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pimitespib in Nonhematologic neoplasms (3 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability of TAS-116 and Pharmacokinetics of TAS-116. Started Feb 2014; status: completed.
02
Drugs
pimitespib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080222394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222394.